Literature DB >> 517048

Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease.

F M Dietrich, J A Fischer, O L Bijvoet.   

Abstract

Low-titre antibodies to synthetic human calcitonin (hCT) were detected in a 69-year-old woman suffering from Paget's disease who was treated for 16 months with hCT and the diphosphonate EHDP. Levels of antibody were highest between 10 and 18 months after commencement of therapy, slowly decreased after completion of treatment and were later no longer measurable. There was no immunological response to a single re-injection of hCT 14 months after discontinuation of therapy. Formation of antibodies to hCT in man is a very rare event, this being the first recorded case of an immune response to synthetic human calcitonin, whereas synthetic salmon calcitonin induces an immune response in a high percentage (up to 78%) of the patients treated with this hormone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 517048     DOI: 10.1530/acta.0.0920468

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  4 in total

1.  Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis.

Authors:  R Muff; M A Dambacher; J A Fischer
Journal:  Osteoporos Int       Date:  1991-02       Impact factor: 4.507

2.  Response of Paget's disease to human calcitonin in patients resistant to porcine calcitonin.

Authors:  V Lo Cascio; S Adami; G Galvanini; R Lazzaretto; M Ferrari; D Tartarotti; L A Scuro
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

Review 3.  Pharmacology and therapeutic use of calcitonin.

Authors:  J C Stevenson; I M Evans
Journal:  Drugs       Date:  1981-04       Impact factor: 9.546

4.  Chronic treatment of Paget's disease of bone with synthetic human calcitonin.

Authors:  R Lang; M Milkman; P S Jensen; A M Vignery
Journal:  Yale J Biol Med       Date:  1981 Sep-Oct
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.